🇺🇸 FDA
Patent

US 8431134

Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen

granted A61KA61K31/00A61K31/53

Quick answer

US patent 8431134 (Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogen) held by The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention expires Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
Grant date
Tue Apr 30 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 25 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
6
CPC classes
A61K, A61K31/00, A61K31/53, A61K38/164, A61K38/1725